

liver fibrosis for choosing a therapeutic strategy if the serum WFA⁺-M2BP examination by the glycan 'sugar chain'-based immunoassay spread more widely in the world.

With regard to the MRI-LMR index, the liver-specific contrast agent, Gd-EOB-DTPA, is widely used to improve the detectability of focal liver lesions and the characterization of liver tumors on MRI [31]. Gd-EOB-DTPA is specifically taken up by hepatocytes. Therefore, the uptake of Gd-EOB-DTPA in the liver could directly reflect the function of the liver, which varies inversely with liver fibrosis. The present study showed that serum WFA⁺-M2BP values had better diagnostic ability than the LMR index in predicting of liver fibrosis \geq F3, with higher areas under the ROC curves (0.812 vs 0.766), sensitivity (88.2 vs 66.7 %), and NPV (94.5 vs 83.5 %). Considering these results, WFA⁺-M2BP values may indicate liver fibrosis, as well as liver function. The specific function of WFA⁺-M2BP in the progress of liver fibrosis urgently needs to be clarified by basic research.

In assessing the heterogeneity of samples, we found that the area under the ROC curves for the diagnosis of fibrosis ($F \geq 3$) using serum WFA⁺-M2BP values was insufficient (0.620) only in the 21 patients positive for HBsAg. Similarly, measurements of liver stiffness, using VTTQ and transient elastography, were shown superior in patients with HCV than in those with HBV [32]. The impact of HBV infection on the function of activated WFA⁺-M2BP in fibrosing liver has not been determined, suggesting the need for further research. In classifying liver inflammation in the 160 patients ($n = 160$) as A1-A4 by the METAVIR grading system, we found that 33 were classified as A0 (2.04 ± 0.39), 73 as A1 (2.75 ± 0.26), 38 as A2 (2.70 ± 0.37), 16 as A3 (2.11 ± 0.56), and none as A4 by the METAVIR grading system [33]. WFA⁺-M2BP levels did not correlate significantly with hepatic inflammatory activity in the general patient cohort and in the three groups, those with HCV, with HBV, and nonBnonC. These findings are in agreement with those of previous reports [10, 11], which did not observe a correlation between WFA⁺-M2BP levels and inflammatory activity. Further research is needed to clarify the molecular mechanisms of hepatic WFA⁺-M2BP production in patients with different etiologies and inflammatory grades of hepatitis.

The previous report [34] analyzed the ability of serum M2BP levels to predict liver fibrosis only in patients with HCV [34]. In that study, however, M2BP concentrations could distinguish only between patients classified as F4 and those classified as F0, F1, or F2, but could not differentiate patients classified as F0 to F3. Our previous reports [10, 11] showed that a WFA-antibody sandwich ELISA (glycan-based immunoassay) was superior to screening with monoclonal anti-M2BP antibody in accelerated stability

and spiking tests by using lectin microarray analysis and human embryonic kidney 293 (HEK293) cells [10, 11]. Human endogenous M2BP consists of 10–16 monomers, each weighing 1000–1500 kDa, with 70–112 *N*-glycans attached to each macromolecule [34]. Since alterations in M2BP during the progression of liver disease and fibrosis were due to changes in *N*-glycosylation, measurements of serum hyperglycosylated WFA⁺-M2BP by glycan-based immunoassays, FastLec-Hepa, seemed reasonable.

In conclusion, examination of serum WFA⁺-M2BP values based on a glycan-based immunoassay is an accurate, reliable, and reproducible method with which to assess liver fibrosis in patients with hepatitis. This approach could be clinically feasible for evaluation of beneficial therapy through the quantification of liver fibrosis in hepatitis patients if this measurement application is commercially realized.

Acknowledgments This study was supported by a Grant-in-Aid from the Ministry of Health, Labour and Welfare, Japan (H23-kan-nen-011). This research was performed by the Hepatitis Glyco-bio-marker Study Group.

Conflict of interest The authors declare that they have no conflict of interest and have no financial interests linked to this work.

References

- Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med*. 1996;334:693–9.
- Shirabe K, Takeishi K, Taketomi A, et al. Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era. *World J Surg*. 2011;35:1072–84.
- Bravo AA, Sheth SG, Chopra S. Liver biopsy. *N Engl J Med*. 2001;344:495–500.
- Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. *Lancet*. 1986;327:523–5.
- Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology*. 2003;38:1449–57.
- Shirabe K, Toshima T, Taketomi A, et al. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan. *Liver Int*. 2011;31:1366–72.
- Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet*. 2001;357:1069–75.
- Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology*. 2002;36:986–92.
- Toshima T, Shirabe K, Takeishi K, et al. New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver. *J Gastroenterol*. 2011;46:705–11.
- Kuno A, Ikehara Y, Tanaka Y, et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. *Sci Rep*. 2013;3:1065.

11. Kuno A, Sato T, Shimazaki H, et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. *Proteomics Clin Appl.* 2013;. doi:10.1002/prca.201300010.
12. Ninomiya M, Shirabe K, Ijichi H, et al. Temporal changes in the stiffness of the remnant liver and spleen after donor hepatectomy as assessed by acoustic radiation force impulse: a preliminary study. *Hepatol Res.* 2011;41:579–86.
13. Harada N, Shirabe K, Ijichi H, et al. Acoustic radiation force impulse imaging predicts postoperative ascites resulting from curative hepatic resection for hepatocellular carcinoma. *Surgery.* 2012;151:837–43.
14. Nishie A, Asayama Y, Ishigami K, et al. MR prediction of liver fibrosis using a liver-specific contrast agent: superparamagnetic iron oxide versus Gd-EOB-DTPA. *J Magn Reson Imaging.* 2012;36:664–71.
15. Boadella M, Gortázar C. Effect of haemolysis and repeated freeze-thawing cycles on wild boar serum antibody testing by ELISA. *BMC Res Notes.* 2011;4:498.
16. Dahl JJ, Pinton GF, Palmeri ML, et al. A parallel tracking method for acoustic radiation force impulse imaging. *IEEE Trans Ultrason Ferroelectr Freq Control.* 2007;54:301–12.
17. Garra BS. Imaging and estimation of tissue elasticity by ultrasound. *Ultrasound Q.* 2007;23:255–68.
18. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology.* 1994;20:15–20.
19. Harada N, Soejima Y, Taketomi A, et al. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. *Transplantation.* 2008;85:69–74.
20. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology.* 2005;41:48–54.
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the area under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics.* 1988;44:837–45.
22. Iacobelli S, Sismondi P, Giai M, et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. *Br J Cancer.* 1994;69:172–6.
23. Shirure VS, Reynolds NM, Burdick MM. Mac-2 binding protein is a novel E-selectin ligand expressed by breast cancer cells. *PLoS One.* 2012;7:e44529.
24. Hu J, He J, Kuang Y, et al. Expression and significance of 90K/Mac-2BP in prostate cancer. *Exp Ther Med.* 2013;5:181–4.
25. Sun L, Chen L, Sun L, et al. Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 Binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer. *Mol Cell Proteomics.* 2013;12:395–406.
26. Inohara H, Akahani S, Koths K, et al. Interactions between galectin-3 and Mac-2-binding protein mediate cell–cell adhesion. *Cancer Res.* 1996;56:4530–4.
27. Ulmer TA, Keeler V, Loh L, et al. Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. *J Cell Biochem.* 2006;98:1351–66.
28. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. *Ann Intern Med.* 1999;131:174–81.
29. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. *J Hepatol.* 1998;28:930–8.
30. Palmeri ML, Wang MH, Rouze NC, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. *J Hepatol.* 2011;55:666–72.
31. Takayama Y, Nishie A, Asayama Y, et al. Image quality of Gd-EOB-DTPA-enhanced magnetic resonance imaging of the liver using dual-source parallel radiofrequency transmission technology: comparison with the post-processing correction method for B1 inhomogeneity-induced signal loss. *Eur J Radiol.* 2012;81:3035–40.
32. Sporea I, Sirlu R, Bota S, et al. Comparative study concerning the value of acoustic radiation force impulse elastography (ARFI) in comparison with transient elastography (TE) for the assessment of liver fibrosis in patients with chronic hepatitis B and C. *Ultrasound Med Biol.* 2012;38:1310–6.
33. The French METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology.* 1996;24:289–93.
34. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. *J Viral Hepat.* 2009;16:418–29.

High-sensitivity *Lens culinaris* agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma

Takashi Kumada · Hidenori Toyoda · Toshifumi Tada · Seiki Kiriyaama · Makoto Tanikawa · Yasuhiro Hisanaga · Akira Kanamori · Junko Tanaka · Chiaki Kagebayashi · Shinji Satomura

Received: 19 May 2013 / Accepted: 5 September 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract

Background Prognosis of patients with hepatocellular carcinoma (HCC) remains poor because HCC is frequently diagnosed late. Therefore, regular surveillance has been recommended to detect HCC at the early stage when curative treatments can be applied. HCC biomarkers, including *Lens culinaris* agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3), are widely used for surveillance in Japan. A newly developed immunoassay system measures AFP-L3 % with high sensitivity. This retrospective study aimed to evaluate clinical utility of high-sensitivity AFP-L3 (hs-AFP-L3) as a predictor of early stage HCC in surveillance at a single site.

Methods Of consecutive 2830 patients in the surveillance between 2000 and 2009, 104 HCC-developed and 104 non-HCC patients were selected by eligibility criteria and propensity score matching. Samples were obtained from the HCC patients who had blood drawn annually for 3 years prior to HCC diagnosis.

Results In the present study, hs-AFP-L3 was elevated 1 year prior to diagnosis in 34.3 % of patients. The

survival rate of patients with the hs-AFP-L3 ≥ 7 % at 1 year prior to diagnosis was significantly lower than that of patients with hs-AFP-L3 < 7 %.

Conclusions Elevation of hs-AFP-L3 was early predictive of development of HCC even at low AFP levels and in absence of ultrasound findings of suspicious HCC. The hs-AFP-L3 should be added to surveillance programs with US because elevated hs-AFP-L3 may be a trigger to perform enhanced imaging modalities for confirmation of HCC.

Keywords Surveillance · A propensity score analysis · High-sensitivity AFP-L3 · DCP · HCC

Abbreviations

| | |
|-----------|---|
| HCC | Hepatocellular carcinoma |
| AFP | Alpha-fetoprotein |
| AFP-L3 | <i>Lens culinaris</i> agglutinin-reactive fraction of AFP |
| hs-AFP-L3 | High-sensitivity AFP-L3 |
| US | Ultrasound |
| DCP | Des-gamma-carboxy prothrombin |
| HBsAg | Hepatitis B surface antigen |
| HCV | Hepatitis C virus |
| ALT | Alanine aminotransferase |
| MRI | Magnetic resonance imaging |

T. Kumada (✉) · H. Toyoda · T. Tada · S. Kiriyaama · M. Tanikawa · Y. Hisanaga · A. Kanamori
Department of Gastroenterology and Hepatology,
Ogaki Municipal Hospital, 4-86 Minaminokawa-cho,
Ogaki, Gifu 503-8052, Japan
e-mail: hosp3@omh.ogaki.gifu.jp

J. Tanaka
Department of Epidemiology Infectious Disease Control and
Prevention, Hiroshima University Institute of Biomedical and
Health Sciences, Hiroshima, Japan

C. Kagebayashi · S. Satomura
Diagnostic Division, Wako Pure Chemical Industries Ltd.,
Osaka, Japan

Introduction

Hepatocellular carcinoma (HCC) is the third most common cause of death from cancer worldwide [1], and poor prognosis is reported because HCC is frequently diagnosed at late stages and is often untreatable. Therefore, surveillance for HCC has been advocated to detect HCC at

early stages when curative treatments can be applied [2, 3]. Global liver associations, including the American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), and the Asian Pacific Association for the Study of the Liver (APASL), recommend regular surveillance on patients at high risk for HCC [4–6]. The most common tests used for surveillance are alpha-fetoprotein (AFP) tests and ultrasound (US). EASL and APASL adopt AFP and US in their guidelines, while AASLD recommends only US. Interpretation of US can be challenging when routine screening and comparison to previous imaging results are impossible or when US are performed by different institutes or instruments, whereas HCC biomarker values can be used independently with appropriate cutoff values. The Japan Society of Hepatology (JSH) has recommended not only US but also assays of three biomarkers: AFP, *Leus culinaris* agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3), and des-gamma-carboxy prothrombin (DCP) [7].

However, AFP levels are often elevated even in patients with benign liver diseases. The low specificity of AFP has been a cause of concern for use as a HCC marker [8–10]. In contrast, a rate of AFP-L3 in total AFP (AFP-L3 %) has been reported to be highly specific for HCC in many studies [11–13]; however, accurate measurements of AFP-L3 % have been limited to patients having AFP >20 ng/mL by insufficient analytical sensitivity on a conventional assay system that is a liquid-phase binding assay (LiBASys) [14]. Recently, a micro-total analysis system (μ TAS) based lectin-affinity electrophoresis using microfluidics technology has enabled accurate measurements of AFP-L3 % even at low AFP [15]. The high-sensitivity AFP-L3 (hs-AFP-L3) assay has demonstrated improvement in clinical sensitivity and predicting of prognosis in HCC patients with AFP < 20 ng/mL [16–18]. The Liver Cancer Study Group of Japan has reported that 37 % of HCC patients had low AFP (<15 ng/mL) at the HCC diagnosis [19]. They also show that 34 % of patients had tumors with maximum diameter of <2 cm. Early HCC is a distinct clinical entity with a high rate of surgical cure and detection of early HCC results in long-term survival [20]. However, elevated AFP is not always observed in patients with such small tumors. Therefore, the hs-AFP-L3 assay which can measure serum levels at low AFP is expected to improve detection of HCC at the early stage. Moreover, lower cutoff values for hs-AFP-L3 has been considered to improve clinical sensitivity [16–18].

In this study, clinical utility in early prediction of development of HCC in our study cohort under surveillance using hs-AFP-L3 and analyzed retrospectively is reported.

Patients and methods

Patients

The study protocol was approved by the Institutional Ethics Committee of Ogaki Municipal Hospital in January 2009 and was in compliance with the Declaration of Helsinki. Written informed consent for use of stored serum samples for the study was obtained from the enrolled patients.

Between 2000 and 2009, a total of consecutive 2830 patients positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibody who visited the Department of Gastroenterology and Hepatology at Ogaki Municipal Hospital were prospectively enrolled in our HCC surveillance. Of the 2830, 1214 patients met eligibility criteria: HBsAg- or HCV RNA-positive for more than 6 months, follow-up period of >3 years before HCC diagnosis, availability of sera sampled at least twice at 12-month intervals, maximal tumor diameter <3 cm and 3 nodules or less at diagnosis, and no oral intake of warfarin which is a DCP-inducing agent.

Of these 1214 patients, 114 patients had HCC and 1100 patients had no evidence of HCC during follow-up period. To reduce the confounding effects of covariates between HCC and control patients, we selected patients using propensity score matching. Six covariates including age, gender, etiology (HBV or HCV), Child-Pugh classification, platelet number, and alanine aminotransferase (ALT) except tumor markers were used. We computed the propensity score by using logistic regression with the independent variable including age (<65 years or ≤ 65 years), sex (female or male), etiology (HBV or HCV), Child-Pugh classification (A, B, or C), platelet count ($>150 \times 10^3/m^3$ or $\leq 150 \times 10^3/m^3$), and ALT activity (≤ 40 IU/mL or >40 IU/mL) as shown in previous reported cut-off values according to the previous reports [21, 22]. This model yielded a *c* statistic of 0.832 (95 % confidence interval [CI], 0.797–0.866), indicating a strong ability to differentiate between HCC and control patients. Calibration was assessed using the Hosmer–Lemeshow goodness-of-fit test [23]. The *P* value of the calculated propensity score was 0.647 based on the Hosmer–Lemeshow test and showed an absence of bias. We were able to match 104 HCC developed patients to 104 non-HCC developing patients. Table 1 shows demographics of HCC and non-HCC groups. The median of tumor size was 1.9 cm. The 69 % of HCC patients had single tumor and the 86 % of HCC patients were at TNM stage I and II.

Surveillance and diagnosis

According to Clinical Practice Guidelines for Hepatocellular Carcinoma in Japan [7], we performed US and three

Table 1 Demographics and propensity score matching

| Characteristics | | HCC (<i>n</i> = 104) | Non-HCC (<i>n</i> = 104) | <i>P</i> value |
|--|------------------------------|-------------------------------|-----------------------------|----------------|
| Age (years) | Median (range) | 67 (37–81) | 68 (14–84) | 0.980 |
| Gender | Male/female | 58 (56 %)/46 (44 %) | 58 (56 %)/46 (44 %) | 0.889 |
| Etiology | B/C/B + C | 14 (13 %)/89 (86 %)/1 (1 %) | 14 (13 %)/89 (86 %)/1 (1 %) | 1.000 |
| Child-Pugh classification | A/B/C | 82 (79 %)/18 (17 %)/4 (4 %) | 84 (81 %)/17 (16 %)/3 (3 %) | 0.907 |
| ALT (IU/L) | Median (range) | 49 (7–361) | 46 (12–321) | 0.582 |
| Platelet ($\times 10^4/\text{mm}^3$) | Median (range) | 10.1 (3.2–34.0) | 12.1 (2.1–41.4) | 0.150 |
| Tumor size (cm) | Median (25 %, 75 % quartile) | 1.9 (1.5, 2.3) | NA | NA |
| Tumor number | Single/Multiple | 72 (69 %)/32 (31 %) | NA | NA |
| TNM stage | I/II/III | 49 (47 %)/41 (39 %)/14 (14 %) | NA | NA |

biomarker studies (AFP, AFP-L3, and DCP) every 3–4 months and dynamic magnetic resonance imaging (MRI) every 12 months for cirrhosis patients under surveillance. For patients with chronic hepatitis, we performed US and three biomarker studies every 6 months. For diagnostic confirmation of HCC, patients had a dynamic MRI when US suggested progression in nodular lesion, change of echo pattern in nodules, or increased biomarkers: continuous elevation of AFP or increase to AFP 200 ng/mL or more, AFP-L3 15 % or more, or DCP 40 mAU/mL or more. The hs-AFP-L3 assay was not available for the surveillance of those days.

Forty-five patients were diagnosed as HCC histologically (surgical specimen, 39 patients; US-guided needle biopsy specimens, 6 patients). The remaining 59 patients were diagnosed as HCC as typical findings of dynamic MRI including hypervascular in the arterial phase with washout in the portal venous or delayed phase [4].

Treatments

Individual decisions for a primary treatment were generally made on the basis of the guidelines for HCC in Japan [7]. Patients were initially assessed for eligibility for resection. When patients declined or were deemed ineligible for resection, they underwent locoregional ablative therapy (LAT) as a second option or transcatheter arterial chemoembolization (TACE) as a third one. Of the enrolled 104 patients, 99 patients underwent resection (*n* = 39), LAT (*n* = 23), or TACE (*n* = 37: including patients with both LAT and TACE). Five patients did not receive any treatment for HCC. No patient underwent liver transplantation.

Imaging modalities

B-mode US was performed with an Aplio XV or XG ultrasound system (Toshiba Medical System, Tokyo, Japan) equipped with a convex probe (PUT-375BT). MR imaging was performed using a superconducting scanner

operating at 1.5 T (Signa Twin Speed; General Electric Medical Systems, Milwaukee, WI). MR images were obtained in the axial plane with a phased-array multicoil for the body. To scan whole livers, the section thickness was 8–10 mm with 2- and 3-mm intersectional gaps, depending on liver size. Breath-hold T1-weighted in-phase and out-of-phase fast spoiled gradient-recalled echo (SPGR, 200/dual echo [4.3/2.1] [TR/TE], 80° flip angle, one signal averaged) MR images were obtained with a field of view of 36–42 cm and a 256 \times 192 matrix during a 22-s acquisition time. T2-weighted fat suppression fast spin-echo (2000/85 [TR/TE], two signal averaged) MR images with respiratory synchronization were obtained with a field of view of 36–42 cm and a 352 \times 256 matrix. Breath-hold double arterial dynamic fast SPGR images (115/1.2 [TR/TE], 70° flip angle, one signal averaged) were obtained with a field of view of 36–42 cm and 512 \times 192 matrix during a 12-s acquisition time. Dynamic MR images were obtained before and after an antecubital intravenous bolus injection of 0.1 mmol/kg of gadopentetate dimeglumine (Magnevist; Bayer in Japan, Tokyo, Japan) followed by 15–20 ml of a sterile normal saline flush. The optimum timing of start of scanning was decided for each case after 1 ml test injection of gadopentetate dimeglumine. The scan times were about 25, 40, and 60 s, and 2–2.5 min after initiation of the contrast injection, representing the early hepatic artery, late hepatic artery, portal vein, and equilibrium phase, respectively. All MR images except T2-weight MR images were obtained using array spatial sensitivity encoding technique (ASSET).

Assays of hs-AFP-L3, AFP, and DCP

For this retrospective study, the measurements of hs-AFP-L3, AFP, and DCP were achieved by using a microchip capillary electrophoresis and liquid-phase binding assay on μ TASWako i30 auto analyzer (Wako Pure Chemical Industries, Ltd.) [16]. Analytical sensitivity of the μ TAS is 0.3 ng/mL AFP, and percentage of AFP-L3 can be

measured when AFP-L3 is over 0.3 ng/mL. Analytical sensitivity of LiBASys is 0.8 ng/mL AFP, but AFP-L3 % can not be calculated at AFP < 10 ng/mL.

Samples were obtained from 104 HCC patients who had blood drawn annually for 3 years prior to the HCC diagnosis and stored at -80°C until the measurements. In the HCC patients, stored serum samples at -3 years (over 30 months before, $n = 94$), -2 years (from 18 to 30 months before, $n = 97$), -1 year (from 6 to 18 months before, $n = 103$), and 0 year ($n = 104$) at the time of the HCC diagnosis were measured. In the non-HCC patients, similarly, stored serum samples at -3 years ($n = 99$), -2 years ($n = 104$), and -1 year ($n = 102$), and 0 year ($n = 104$) from the end of follow-up were measured.

Statistical analysis

To evaluate the diagnostic accuracy and predictive values of AFP, hs-AFP-L3, and DCP, sensitivity and specificity were calculated with cutoff values in the guidelines [7]. Furthermore, cutoff values of 5, 7, and 10 % for hs-AFP-L3 were used for this retrospective study according to previous reports [13, 16]. Serial changes of three biomarkers before the diagnosis of HCC were analyzed by

Wilcoxon matched pair signed rank test. For the evaluation of prognosis, the long-term survival of patients with HCC was determined by the Kaplan–Meier method and the log-rank test was used to compare the survival rates. The values were considered significant when P value was < 0.05 . The analyses were performed using JMP10 statistical software (SAS Institute Japan, Japan).

The propensity score matching was performed with SPSS, version 18.0 for Windows (International Business Machines Corporation, Tokyo, Japan).

Results

Dynamic changes of biomarkers

The dynamic changes of hs-AFP-L3, AFP, and DCP in HCC patients at -3 , -2 , -1 , and 0 year before diagnosis are shown in Fig. 1a, b, and c. The levels of hs-AFP-L3 at -1 year were significantly elevated from the levels at -2 years ($P = 0.0001$). The levels of hs-AFP-L3 at -0 year were significantly elevated from the levels at -1 year ($P = 0.0003$, Table 2). AFP and DCP were significantly elevated between -1 and 0 year ($P = 0.0315$




Fig. 1 Dynamic changes of biomarkers: **a** hs-AFP-L3, **b** AFP, and **c** DCP in each HCC patient ($n = 104$), and **d** hs-AFP-L3, **e** AFP, and **f** DCP in each non-HCC patient ($n = 104$)

Table 2 Serial changes of three biomarkers in HCC patients (Wilcoxon matched pair signed rank test)

| Analyte | P value | | |
|-----------|------------------------|------------------------|-----------------------|
| | At -3 year and -2 year | At -2 year and -1 year | At -1 year and 0 year |
| hs-AFP-L3 | 0.2935 | 0.0001 | 0.0003 |
| AFP | 0.4278 | 0.5359 | 0.0315 |
| DCP | 0.0926 | 0.6302 | <0.0001 |

and $P < 0.0001$, respectively, Table 2). In non-HCC patients, no significant differences were observed for any markers (Fig. 1d–f). Only hs-AFP-L3 in HCC patients were significantly elevated 1 year prior to HCC diagnosis.

Sensitivity and specificity at diagnosis

Diagnostic sensitivity and specificity were evaluated for the hs-AFP-L3, AFP, DCP, and the combination of biomarkers (Table 3). The sensitivity was calculated by using HCC patient samples at diagnosis ($n = 104$) and the specificity was calculated by using non-HCC patient samples at -3 years ($n = 100$) to ensure that none had developed HCC for the following 3 years. Of the 104 HCC patients, 43 patients (41.3 %) had AFP < 10 ng/mL at which the conventional assay was not able to calculate AFP-L3 %. The sensitivity and specificity for hs-AFP-L3 were 11.5 and 100.0 %, respectively at a cutoff value of 15 %. A cutoff value of 7 % improved the sensitivity to 39.4 %. A combination assay with hs-AFP-L3, AFP, and DCP resulted in sensitivity of 60.6 % at diagnosis.

Sensitivity and specificity for 3 years before diagnosis

We calculated sensitivities using HCC samples at 3, 2, and 1 years prior to diagnosis. Similarly, specificities were

Table 3 Sensitivity and specificity at diagnosis

| Analyte | Cutoff | Sensitivity (%) | Specificity (%) |
|----------------|-----------------------------|-----------------|-----------------|
| hs-AFP-L3 | 5 % | 50.9 | 51.0 |
| | 7 % | 39.4 | 77.0 |
| | 10 % | 16.3 | 96.0 |
| | 15 % | 11.5 | 100.0 |
| AFP | 20 ng/mL | 41.4 | 90.4 |
| | 200 ng/mL | 12.5 | 99.0 |
| DCP | 40 mAU/mL | 34.6 | 94.0 |
| All biomarkers | 7 % + 200 ng/mL + 40 mAU/mL | 60.6 | 76.0 |

calculated by using non-HCC samples (Table 4). The sensitivity and specificity for hs-AFP-L3 at -1 year were 34.3 and 74.7 %, respectively. The sensitivities at -1 year for AFP and DCP were 35.0 and 12.1 %, respectively. In HCC patients, hs-AFP-L3 turned positive at 34 patients (33.3 %) and stayed in positive at 27 patients (26.2 %) for two years till the diagnosis of HCC. In contrast, hs-AFP-L3 turned positive at 25 patients (24.3 %) and stayed in positive at 22 patients (21.4 %) for 2 years till the end of follow-up in non-HCC patients.

Comparison of tumor characteristics and survival rates

Comparing tumor characteristics at detection of HCC by a level of hs-AFP-L3 at -1 year, the tumor size, the number of tumors, and TNM stage between patients with hs-AFP-L3 ≥ 7 % and <7 % ($P = 0.064$, 0.821, and 0.504, respectively) were not statistically significant. The number of patients receiving curative treatments such as resection and LAT was significantly higher in patients with hs-AFP-L3 < 7 % ($P = 0.020$) (data not shown).

During the follow-up period after the diagnosis that was ranged from 4 to 110 months (median of 39 months), the survival rate of patients with hs-AFP-L3 ≥ 7 % was significantly lower than that of patients with hs-AFP-L3 < 7 % by using values at -1 year ($P = 0.039$) (Fig. 2). There was no statistical significance between patients with DCP ≥ 40 mAU/mL and patients with DCP < 40 mAU/mL ($P = 0.831$). No patients had AFP > 200 ng/mL at -1 year. The survival rate of patients with hs-AFP-L3 ≥ 7 % had a lower tendency than that of patients with hs-AFP-L3 < 7 % at HCC diagnosis ($P = 0.1501$).


Triggers to perform MRI for suspicious HCC and positivity rates for hs-AFP-L3

In this study population, US was performed median of 4 times between -1 year and diagnosis day. The 104 HCC

Table 4 Sensitivity and specificity for three years before diagnosis

| Analyte | Year | Sensitivity (%) | Specificity (%) |
|----------------------|------|-----------------|-----------------|
| hs-AFP-L3 ≥ 7 % | -1 | 34.3 | 74.7 |
| | -2 | 25.3 | 80.6 |
| | -3 | 24.5 | 77.0 |
| AFP ≥ 20 ng/mL | -1 | 35.0 | 86.4 |
| | -2 | 31.0 | 83.0 |
| DCP ≥ 40 mAU/mL | -3 | 33.0 | 86.0 |
| | -1 | 12.1 | 93.9 |
| | -2 | 8.4 | 94.9 |
| | -3 | 4.3 | 94.0 |

Fig. 2 Survival rates by levels of biomarkers: **a** hs-AFP-L3 and **b** DCP 1 year before, **c** hs-AFP-L3 and **d** DCP at diagnosis



patients were classified into three groups by a trigger to perform MRI for diagnostic confirmation (Table 5). US findings triggered MRI for 86 patients. The 86 patients were classified further by US findings: increase of the tumor number (51/86), increase of the tumor size (18/86), or change of the echo pattern in nodules (17/86). Five patients were monitored by MRI as results of elevated biomarkers. The remaining 13 patients were screened by MRI instead of US because interpretation of US was

difficult in patients who were obese or had severe liver atrophy.

In the present retrospective study for hs-AFP-L3, 29.6 % of patients who were diagnosed with HCC by the trigger of US had hs-AFP-L3 $\geq 7\%$ 1 year prior to the diagnosis day. In the patients who had changes of the echo pattern in nodules, the positivity rate for hs-AFP-L3 at -1 year was 50.0 % and relatively higher compared to the other groups by US.

Table 5 Triggers to perform MRI for suspicious HCC and positivity rates for hs-AFP-L3

| Triggers to perform MRI | <i>n</i> | hs-AFP-L3 $>7\%$ At -1 year (%) | hs-AFP-L3 $>7\%$ At diagnosis (%) |
|---------------------------------------|----------|-----------------------------------|-----------------------------------|
| (a) Ultrasound | 86 | 29.6 | 36.0 |
| Increase of the tumor number | 51 | 27.7 | 39.2 |
| Increase of the tumor size | 18 | 16.7 | 11.1 |
| Change of the echo pattern in nodules | 17 | 50.0 | 52.9 |
| (b) Biomarkers | 5 | 80.0 | 60.0 |
| (c) Others | 13 | 46.2 | 53.8 |

Discussion

Most studies on HCC biomarkers have focused on the accuracy at the time of diagnosis and the prediction of prognosis. So far there are a few studies which have evaluated early prediction of development of HCC in patients at high risk for HCC by biomarkers.

Taketa et al. [24] have reported that AFP-L3 values elevated above the cutoff value of 15 % with an average of 4.0 ± 4.9 months before the detection of HCC by imaging techniques. Sato et al. [25] also have demonstrated that lectin-reactive AFP elevated 3–18 months before the detection. However, only samples with AFP levels higher than 30 ng/mL were measured in their study. Recent data

indicated that the elevated AFP is not typical at HCC diagnosis for patients under in surveillance in Japan. Therefore, hs-AFP-L3 is expected to be more useful at low levels of AFP. Even though there were some differences in AFP concentration among the studies, they reported that elevation of AFP-L3 prior to diagnosis was associated with development of HCC.

Shiraki et al. [26] detected the small tumor <2 cm in maximum diameter in more than half of the patients. In the study population, they demonstrated clinical utility of lectin-reactive AFP as an early indicator while low AFP was reported limiting of the early recognition of HCC. Shimauchi et al. [27] demonstrated that AFP-L3 and DCP values showed elevated in about half of the patients at 6 months before the recognition of HCC by imaging techniques. These two markers were mutually complementary. In our study, DCP was not significantly elevated 1 year prior to diagnosis.

Lok et al. [28] have reported in a retrospective study of AFP and DCP values in patients in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial who had blood drawn every 3 months for 12 months prior to HCC diagnosis. They have concluded that the biomarkers are needed to complement ultrasound in the detection of early HCC but neither DCP nor AFP is optimal. For the study, early stage HCC was defined as a single tumor nodule <3 cm in diameter with no evidence of vascular invasion or metastasis, and only 61.5 % of patients presented with early stage HCC. In our study, median of tumor size was 1.9 cm and all patients with <3 cm. Tumor volume doubling time is reported to be 90–132 days [29] and it may take a half year or 1 year for a nodule to develop from <2 cm to >3 cm. Therefore, HCC patients in our study were diagnosed 1 year earlier than the patients in Lok's study. Clinically the tumor size between <2 cm and 3 cm is one of the factor for making decisions of treatments, and it has been reported that survival rate of patients with tumor size <2 cm is higher [20]. Therefore, HCC should be diagnosed at the earlier stage with tumor <2 cm in order to achieve better outcome.

It is well known that AFP-L3 concentration correlates well with AFP; however, AFP-L3 % is not correlated with AFP [24, 30]. AFP-L3 % is a marker that is independent of AFP. Therefore, we have used AFP-L3 % for analysis.

In the present study, hs-AFP-L3 was significantly elevated 1 year prior to HCC diagnosis in 34.3 % of patients at a cutoff value of 7 %. Tamura et al. [16] reported that a cutoff value of 7 % is most appropriate for discriminating HCC from benign liver disease using this assay. Therefore, patients with elevated hs-AFP-L3 value under surveillance should be followed up closely. The specificity of 80 % or less before diagnosis may actually mislead because the non-HCC patients selected by matching with the HCC

patients were potentially higher risk group for HCC and would likely develop HCC later.

In previous studies, elevated AFP-L3 has been reported to be correlated to a shorter doubling time of tumor volume, increased hepatic arterial supply, and pathologic features such as infiltrative tumor growth pattern, capsule infiltration, vascular invasion, and intrahepatic metastasis [31, 32]. These findings are often difficult to diagnose by various imaging modalities in small HCCs. Such blood supply changes typically result in change of echo pattern in nodules. In this study, therefore, high positivity rates for hs-AFP-L3 at -1 year in the patients who had such changes of echo pattern may be associated with developing HCC. The survival rate of patients with hs-AFP-L3 > 7 % at -1 year was significantly poorer compared to patients with hs-AFP-L3 < 7 %. However, differences of the detected tumor size and number were not statistically significant between patients with hs-AFP-L3 ≥ 7 % and < 7 %. AFP-L3-positive HCC nodules may be aggressive and have high malignancy potential even though the tumor size is small. Therefore, it may be useful in early detection of the aggressive tumor to perform enhanced imaging techniques such as MRI for patients with elevated hs-AFP-L3. Survival rate of patients with the hs-AFP-L3 elevation at HCC diagnosis showed a poorer tendency; however, there were no statistical differences. HCC treatments were done just after the HCC diagnosis. Therefore, HCC tumors in patients with the hs-AFP-L3 elevation 1 year before HCC diagnosis might have 1 year to grow. This 1 year may reflect the difference of survival of two groups. DCP is a good marker for poor prognosis of HCC. However, the difference of overall survival between patients with DCP ≥ 40 and < 40 mAU/mL was not observed due to the early stage (small) HCC without obvious vascular invasion.

AFP is a good marker to distinguish high-risk group for HCC development in the future [22]; however, AFP was not elevated 1 year prior to HCC development. AFP-L3 was elevated 1 year prior to diagnosis of small HCC in 34.3 % of patients.

Interpretation of US can be challenging without comparison to previous imaging results and performance of US can be limited in patients who are obese or have severe background liver cirrhosis. In the present study, sensitivity of the combined three biomarkers was 60.6 % at diagnosis, and measurements of biomarkers are expected to complement to US in surveillance.

In conclusion, elevation of hs-AFP-L3 was early predictive of development of HCC even at low AFP levels and in absence of US findings of suspicious HCC. Prognosis of patients with elevated hs-AFP-L3 was significantly poorer. HCC may be diagnosed earlier to receive curative treatments by the elevated hs-AFP-L3 as a trigger of enhanced imaging techniques. Additional prospective studies are

expected to demonstrate whether routine measurements of hs-AFP-L3 in HCC surveillance can improve overall patient survival.

Acknowledgments This work was supported by Health and Labour Sciences Research Grants (Research on Hepatitis) from the Ministry of Health, Labour and Welfare of Japan.

Conflict of interest All authors declare that the authors report no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010;127:2893–917.
2. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol*. 2004;130:417–22.
3. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. *Hepatology*. 2000;32:842–6.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011;53:1020–2.
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. *J Hepatol*. 2001;35:421–30.
6. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. *Hepatology Int*. 2010;4:439–74.
7. Makuuchi M, Kokudo N, Arai S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. *Hepatol Res*. 2008;38:37–51.
8. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. *Cancer*. 1989;64:2117–20.
9. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. *Liver*. 1986;6:133–7.
10. Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. *J Clin Gastroenterol*. 2001;32:240–4.
11. Aoyagi Y, Isemura M, Suzuki Y, Sekine C, Soga K, Ozaki T, et al. Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. *Lancet*. 1985;2:1353–4.
12. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. *Gastroenterology*. 1990;99:508–18.
13. Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of *Lens culinaris* agglutinin-reactive alpha-fetoprotein. *J Gastroenterol Hepatol*. 2001;16:1378–83.
14. Yamagata Y, Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S. Determination of alpha-fetoprotein concentration based on liquid-phase binding assay using anion exchange chromatography and sulfated peptide introduced antibody. *J Immunol Methods*. 1998;212:161–8.
15. Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. *Anal Biochem*. 2009;388:306–11.
16. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. *Dig Dis Sci*. 2010;55:2095–101.
17. Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, Akagi S, et al. Clinical significance of the highly sensitive fucosylated fraction of alpha-fetoprotein in patients with chronic liver disease. *J Gastroenterol Hepatol*. 2011;26:739–44.
18. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, et al. Clinical utility of highly sensitive *Lens culinaris* agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. *Cancer Sci*. 2011;102:1025–31.
19. Ikai I, Kudo M, Arai S, Omata M, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. *Hepatol Res*. 2010;40:1043–59.
20. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. *Hepatology*. 1998;28:1241–6.
21. Kumada T, Toyoda H, Kiriya S, Sone Y, Tanikawa M, Hisanaga Y, et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. *J Hepatol*. 2009;50:729–35.
22. Kumada T, Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, et al. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. *J Gastroenterol*. 2011;46:536–44.
23. Hosmer DW, Lemeshow S. *Applied logistic regression*. New York: Wiley; 2000.
24. Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive a-fetoproteins in early detection of hepatocellular carcinoma. *Cancer Res*. 1993;53:5419–23.
25. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. *N Engl J Med*. 1993;328:1802–6.
26. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. *Hepatology*. 1995;22:802–7. *Oncol Rep*. 2000; 7: 249–256.
27. Shimauchi Y, Tanaka M, Kuromatsu R, Ogata R, Tateishi Y, Itano S, et al. A simultaneous monitoring of *Lens culinaris* agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. *Oncol Rep*. 2000;7:249–56.
28. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. *Gastroenterology*. 2010;138:493–502.
29. Okazaki N, Yoshino M, Yoshida T, Suzuki M, Moriyama N, Takayasu K, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. *Cancer*. 1989;63:2207–10.